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Background: Dilatation of the artery proximal to arteriovenous fistula (AF) is not well known but is a potential serious
complication in patients for renal transplant.
Methods: From 1991 until 2001, the diameters of the brachial arteries of 29 patients after successful renal transplantation
and with existing AF were prospectively evaluated with ultrasound scan. Nine patients with longstanding AF without
transplantation were included as a control group.
Results: In 1991, the mean brachial artery diameter was 6.4 mm (1.8 mm) with patent AF and 5.2 mm (1.5 mm) with
occluded AF (P not significant). The 1994 mean diameter was 6.6 mm (1.7 mm) versus 5.3 mm (2.0 mm; P .029).
In 2001, the mean diameter rose to 7.4 mm (1.3 mm) versus 5.7 mm (2.8 mm; P  .022). Compared with the side
without fistula, the diameter of brachial artery on the AF side was significantly greater during the whole study period. The
increase in the diameter correlates significantly with the time the AF had been patent (P  .001, according to Spearman
test). The dilatation of the brachial arteries of patients without transplantation was smaller compared with patients after
transplantation but did not reach statistical significance. Two patients had to undergo operation on a symptomatic
aneurysm of the axillobrachial artery.
Conclusion: According to our results, dilatation of the brachial artery after AV is time dependent. Higher flow in the AF
seems to be the main trigger of dilatation. (J Vasc Surg 2003;37:564-7.)
Aneurysmal dilatation proximal to longstanding arte-
riovenous fistulae (AF) is a known but not well-investigated
phenomenon.1-3 Hunter4,5 first described the develop-
ment of arterial dilatation from longstanding AF in 1757.
Most of the arterial dilatation occurred after traumatic AF
and aneurysmal progression even after ligation of the fistula
was recorded.6-13 Possible explanations for these findings
are increased flow in the vessel14 and endothelium-derived
factors.15,16 In our study, we investigated brachial arterial
dilatation in patients after renal transplantation (rTPX) and
long-lasting AF.
METHODS
Patient population. In 1991, all patients after rTPX
or planed transplantation were prospectively included in
the study. They were followed until February 2001. All
patients could be followed either until the end of the
observation period or until the death of the patient. As a
baseline investigation, diameters of brachial arteries of
the left and the right upper extremities were recorded
with ultrasound scan. In 1994 and 2001, control ultra-
sound scan was scheduled. As a control group, nine
patients with longstanding AF without transplantation
were examined. Dilatation of the brachial arteries was
determined according to the definition by the subcom-
mittee on reporting standards for arterial aneurysms.17
Baseline data included patient demographics, smoking
history, status, and kind of AF (Table I).
Definition of outcomes. The primary outcome was
the change of diameter of the brachial arteries. Secondary
outcomes were time of occlusion (surgical or spontaneous)
of AF and complications related to arterial dilatation. Only
complications leading to surgical interventions were re-
corded.
Statistical analysis. The diameters of the brachial
arteries were compared between sides with Wilcoxon
signed rank test (nonparametric test). Correlation between
diameter and patency of AF was calculated with the Spear-
men test (nonparametric correlation). P values of less than
.05 were considered significant.
RESULTS
Patient population. Twenty-nine patients after rTPX
were included in the study. Twenty-six patients actually had
undergone successful rTPX, and the other three were on a
waiting list and underwent transplantation in the following
year. As a control group, nine patients with longstanding
AF were compared in 2002.
In 1994, 26 patients (90%) and, in 2001, 19 patients
(66%) were still alive. The mean age at the beginning of
the study in 1991 was 54 years (12.5 years; range, 29
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to 74 years) in patients after rTPX and 61 years (18
years; range, 34 to 81 years) in 2002 for patients without
transplant (P  not significant). Most of the AF were at
the forearm (25 AF; 86%, in the group after rTPX; and
five; 63%, without transplantation; Table II). In the
rTPX group in 1991, 20 AF were patent (69%) and the
mean patency time was 72 months. In 1994 (2001), 14
AF (10) were still patent for a mean time of 109 (194)
months (Table II). The mean follow-up time in the
control group was 86 months, and all AF were patent at
the time of investigation.
Brachial artery dilatation. According to the sugges-
tions of the subcommittee, the normal diameter of the
brachial artery varies from 3.5 to 4.3 mm for women and
from 4.1 to 4.8 mm for men.17 In the group after rTPX, the
mean brachial artery diameter at the side of the AF of all
patients was, in 1991, 6.4 mm (1.8 mm) if the access was
patent and 5.2 mm (1.5 mm) if it was occluded. In 1994,
the diameter was 6.6 mm (1.7 mm) versus 5.3 mm (2.0
mm), and in 2001, it was 7.4 mm (1.3 mm) versus 5.7
mm (2.8 mm). In 1991, 1994, and 2001, the differences
between artery diameters were significant whether the ac-
Fig 1. Correlation between diameter of brachial artery of 29
patients after rTPX and time (line indicates Spearman correlation).
Table I. Demographics of 37 patients with brachial
artery dilatation and longstanding hemodialysis fistula
Patients after
rTPX
(n  29)
Patients without
rTPX
(n  9)
Age (y) 54 (12.5; 29 to 74) 62 (17.7; 34 to 81)
Male gender 20 (69%) 3 (33%)
Diabetes 3 (10%) 1 (11%)
Hypertension 28 (97%) 4 (44%)
Hyperlipidemia 5 (17%) 2 (22%)
Tobacco use 18 (62%) 5 (55%)
Immunosuppression* None
Corticosteroids 21 (72%)
Azathioprin 23 (79%)
Ciclosporin 22 (76%)
*Some patients received more than one drug.
Table II. Characteristics of 38 AF
With rTPX
(n  29)
No rTPX
(n  9)
Site of arterial anastomosis
Radial 25 (86%) 6 (67%)
Radiocephalic 22 6
Polytetrafluoroethylene-loop 3
Brachial 4 (14%) 3 (33%)
Patency (mean; months)
1991 (n  29) 72
1994 (n  26) 109
2001 (n  19) 194
Patent without rTPX
(n  9)
86
Table III. Diameters (in mm) of brachial arteries according to side and time
Side with AF Contralateral side P value
1991 (n  29)
Patent (n  20) 6.4  1.8 4.3  0.6 .001
Occluded (n  9) 5.2  1.5 4.0  0.5 .02
P value .066 .119
1994 (n  26)
Patent (n  14) 6.6  1.7 4.2  0.9 .001
Occluded (n  12) 5.3  2.0 4.0  0.7 .008
P value .029 .239
2001 (n  19)
Patent (n  10) 7.4  1.3 5.1  0.4 .005
Occluded (n  9) 5.7  2.8 4.5  0.8 .173
P value .022 .252
Control (patent without transplantation; n  9)
5.8  0.6 4.4  0.6 .001
Dilatation (mm) of brachial arteries with patent AF
Transplanted (n  14; 1994) Nontransplanted (n  9)
6.6  1.7 5.8  0.6 Not significant
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 3 Eugster et al 565
cess was patent or occluded (Table III). Comparison of the
side with AF with the other side showed significant differ-
ences at all times (Table III). There was a strong correlation
between patency and arterial diameter according to the
Spearman test (P  .001; r  0.679; Fig 1).
The mean diameter of the brachial artery in the control
group was 6.0 mm (0.5 mm) at the side with AF com-
pared with 4.4 mm (0.6 mm) at the other arm (P .001;
Table III). Because dilatation is time dependent (Fig 1), we
compared the mean follow-up time in 1994 (109 months)
with the mean follow-up time in the control group (86
months). The mean dilatation of the 14 patent AF (6.6
mm) at the group after rTPX was larger than dilatation at
the control group (5.8 mm; Table III) but did not reach
significance.
In 2001, we had to operate on two patients with
symptomatic aneurysmal dilatation of the brachial artery.
One fistula was patent for 125 months, and one was oc-
cluded since 1994 but had been patent for 81 months. In
both patients, distal embolic occlusions of peripheral arter-
ies were present (Fig 2). At operation, the aneurysms were
resected and flow was established with construction of a
bypass with greater saphenous vein.
DISCUSSION
The objective of this study was to compare brachial
artery diameter in long-lasting AF. Dilatation of the artery
proximal to fistulas is noticed either in patent or occluded
fistulas.2,3,6-8 The major part of these dilatations have been
observed in traumatic fistulas.9-12 Only one publication
recently reported a symptomatic aneurysmal dilatation of
the axillobrachial artery after long-lasting hemodialysis ac-
cess.1
Sako and Varco14 reported in 1970 on a total of 57
AVFs. Thirty-two patients had congenital forms of AF, and
25 had acquired forms. They thought that the mechanism
underlying dilatation to be from stress, high blood flow,
and interference with the function of the vasa vasorum.
Microscopic sections of the arterial wall of operated aneu-
rysms proximal to AF did show fragmentation of the elastic
tissue, atrophy of the muscles, increased fibrosis, intimal
thickening, and calcification in some areas. The overall
appearance of the artery was similar to that of an arterio-
sclerotic aneurysm. Even after removal of the AF, dilatation
of the artery may progress. Therefore, they recommended
an investigation of the artery in every patient with a fistula
of long duration. In 1986, Miller, Aarhus, and Van-
houtte15 and Rubanyi, Romero, and Vanhoutte16 postu-
lated a humoral influence. Rubanyi, Romero, and Van-
houtte16 were able to show that flow triggered the release
of relaxing substances from vascular endothelial cells that
had characteristics similar to the endothelium-derived re-
laxing factor released by acetylcholine. The fact that only
the side with the AF showed dilatation supports these
findings and indicates a local rather than a systemic effect
triggering dilatation of the artery.
Our data show a dilatation depending on time. This
dilatation occurred despite half of all AF occluded during
the study period at patients after rTPX. Yet the dilatation of
the artery was significantly smaller if the AF was occluded,
supporting the hypothesis of higher flow leading to arterial
dilatation. This observation is further supported by the fact
that the difference in arterial diameters also was significant
at the control group without transplantation.
The patients after successful kidney transplantation
consecutively received imunosuppression. Twenty-one pa-
Fig 2. Angiography of dilated left axillobrachial artery with peripheral embolic occlusions (patient 2). Dotted line
marks outer dimension of aneurysm.
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tients were receiving corticosteroids. Experimental evi-
dence suggests that corticosteroids may promote both the
development and rupture of aortic aneurysms.18 Aneurys-
mal disease appears more common and develops 10 years
earlier in patients receiving steroids for autoimmune dis-
ease.19 Ammori and coworkers20 recommend early repair
in patients for cardiac transplant with aortic aneurysms.
Because there was a significant difference in arterial
diameter of the arm with the fistula compared with the arm
without fistula, we conclude that the fistula is the main
trigger for dilatation of the artery. In our work, immuno-
suppression is of minor importance but may increase the
total amount of dilatation.
The main limitation to our study is the small number of
patients, making a type 2 statistical error possible. But the
long follow-up period without loss of patients strengthened
the statistical value of our results. The patients in the
control group were not totally comparable with the trans-
plant patients because more women and less patients with
hypertension were included. Arterial diameters in women
are smaller than those in men.17 For that reason, it could be
expected that a potential difference of diameters between
the two groups would be influenced by the disproportional
distribution of women at the control group. One can
expect that the mean diameter would be greater at the
control group if more men were included. Because the
difference of mean diameters between the groups was not
significant, it can be concluded that with inclusion of more
men into the control group the results would be similar.
In summary, our findings support the observation that
dilatation of the artery proximal to AF exists. The main
trigger for this dilatation seems to be increased flow at the
side of the AF. Immunosuppression after kidney transplan-
tation may accelerate this process.
We thank W. Berchtold, PhD, Brugg, Switzerland, for
statistical assistance.
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